BRAINERD — Motorcycle riders and enthusiasts from across the world will soon descend on Brainerd as they work to raise awareness and fight Duchenne muscular dystrophy. Hosted by Brainerd's Craig ...
15d
First successes in the development of a gene therapy for incurable LAMA2-related muscular dystrophy
Researchers at the University of Basel have developed a gene therapy that could potentially treat a rare and currently fatal muscle disease in children. The study shows in animal models that a single ...
Stories by SWNS on MSN
Boy, 7, diagnosed with rare muscular condition after he stopped jumping
A little boy was diagnosed with a life-limiting, muscular condition after his parents realised he was unable to jump. Kairo ...
Amazon S3 on MSN
Dog and kid go viral for surprisingly muscular physiques
Fitness Pro Superhuman Troy captures the viral story of a dog and kid whose surprisingly muscular physiques are inspiring the ...
What Is Itvisma, and Why Does It Matter? Itvisma (onasemnogene abeparvovec-brve) is a gene therapy that the FDA has approved to treat spinal muscular atrophy (SMA) in adults, teens, and children 2 or ...
• The "Fill the Boot" fundraiser ran from 3-6 p.m. and supports research, cures and local families affected by muscular dystrophy • Donations can still be made online through a QR code and dedicated ...
Duchenne muscular dystrophy (DMD) is a genetic condition caused by a change, or mutation, in the DMD gene. This gene normally tells the body how to make dystrophin, a protein that helps protect ...
A RECOMMENDATION for the HSE not to cover the cost of a drug to help children with a rare muscular disease has been blasted by families. Last year, The Irish Sun highlighted the plight of ...
Families affected by the condition and a dedicated support crew walked 92km across Perth over four days to raise funds and ...
If a boy in New York has been convinced to think he’s a girl, the state Medicaid program has got you covered. But if a boy with muscular dystrophy just wants to walk again, he’s in trouble. That’s the ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. So most recently, there has been the ...
Biogen Inc. (NASDAQ:BIIB) on Wednesday announced in a press release the topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results